Back to Search Start Over

Dose tapering, increases, and discontinuity among patients on long-term high-dose opioid therapy in the United States, 2017-2019.

Authors :
Nataraj, Nisha
Strahan, Andrea E.
Guy, Gery P.
Losby, Jan L.
Dowell, Deborah
Guy, Gery P Jr
Source :
Drug & Alcohol Dependence. May2022, Vol. 234, pN.PAG-N.PAG. 1p.
Publication Year :
2022

Abstract

<bold>Background: </bold>While reduced exposure to prescription opioids may decrease risks, including overdose and opioid use disorder, abrupt tapering or discontinuation may pose new risks.<bold>Objectives: </bold>To examine potentially unsafe tapering and discontinuation among dosage changes in opioid prescriptions dispensed to US patients on high-dose long-term opioid therapy.<bold>Design: </bold>Longitudinal observational study of adults (≥18 years) on stable high-dose (≥50 oral morphine milligram equivalents [MME] daily dosage) long-term opioid therapy during a 180-day baseline and a 360-day follow-up using all-payer pharmaceutical claims data, 2017-2019.<bold>Measures: </bold>Dosage tapering, increases, and/or stability during follow-up; sustained dosage stability, reductions, or discontinuation at the end of follow-up; and tapering rate. Patients could experience more than one outcome during follow-up.<bold>Results: </bold>Among 595,078 patients receiving high-dose long-term opioid therapy in the sample, 26.7% experienced sustained dosage reductions and 9.3% experienced discontinuation. Among patients experiencing tapering, 62.0% experienced maximum taper rates between > 10-40% reductions per month and 36.1% experienced monthly rates ≥ 40%. Among patients with mean baseline daily dosages ≥ 150 MME, 47.7% experienced a maximum taper rate ≥ 40% per month. Relative to baseline, 19.7% of patients experiencing tapering had long-term dosage reductions ≥ 40% per month at the end of follow-up.<bold>Implications: </bold>Dosage changes for patients on high-dose long-term opioid therapy may warrant special attention, particularly over shorter intervals, to understand how potentially sudden tapering and discontinuation can be reduced while emphasizing patient safety and shared decision-making. Rapid discontinuation of opioids can increase risk of adverse outcomes including opioid withdrawal. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03768716
Volume :
234
Database :
Academic Search Index
Journal :
Drug & Alcohol Dependence
Publication Type :
Academic Journal
Accession number :
156287124
Full Text :
https://doi.org/10.1016/j.drugalcdep.2022.109392